Skip to main content
Category

Press Release

T-Therapeutics appoints Theodora Harold as Chief Executive Officer, reflecting Company’s ambitious growth plans and progression into therapeutic development

Theodora has over 25 years’ experience in the biotech sector, with a proven track record of dynamic leadership. 10 March 2025; Cambridge, England – T-Therapeutics, a biotechnology company developing next-generation soluble T cell receptor (TCR) therapeutics targeting cancer and autoimmune indications, announces the…
Read More

T-Therapeutics appoints Dr David Hung as Chairman

Industry veteran, founder of Medivation and serial entrepreneur joins T-Therapeutics to support development of the company’s pipeline of TCR-based immuno-oncology drugs 12 June 2024; Cambridge, England – T-Therapeutics, a biotechnology company developing next-generation soluble TCR therapeutics targeting cancer and autoimmune indications, today announces…
Read More